Summary In a prospective trial of 75 Chinese patients with histologically proven inoperable hepatocellular carcinoma (HCC), 25 patients were randomised to receive doxorubicin 60-75 mg m2 intravenously once every 3 weeks, 25 to receive recombinant M2 interferon (rIFN) (Roferon) 9-18 x 106 IU m-2 intramuscularly (i.m.) daily and 25 to receive rIFN 25-50 x 106 IU m-2 i.m. three times weekly. Patients were switched to the other drug if: (a) there was progressive disease after 12 weeks, (b) unacceptable toxicity developed and (c) they had received a total of 500 mg m2 of doxorubicin. Six patients had switching over of therapy, three on doxorubicin and three on rIFN. In the remaining 69 patients on single drug therapy, the median survival rate of patients on doxorubicin and rIFN was 4.8 and 8.3 weeks respectively (P = ns.). rIFN induced tumour regression of 25-50% in 12% of patients and of over 50% in 10% of patients. When compared with doxorubicin, rIFN was associated with more tumour regression (P = 0.00199) and less progressive tumours (P= 0.00017). It caused less prolonged and less severe marrow suppression (P= 0.01217), and had significantly less fatal complications than doxorubicin (P = 0.01383). Doxorubicin caused fatal complications due to cardiotoxicity and neutropenia in 25% of patients. rIFN was associated with fatal complications due to dementia and renal failure in 3.8% of patients. In the treatment of inoperable HCC, rIFN is superior to doxorubicin in causing more tumour regression, less serious marrow suppression and less fatal complications.
Hepatocellular carcinoma (HCC) is one of the 10 commonest cancers in the world (WHO, 1983) , probably the commonest cancer affecting males, with an estimated annual incidence of 1,000,000 cases (Biscaegli et al., 1988; London, 1981) . The majority (over 95%) of those who present are not operable (Lai et al., 1981) .
Doxorubicin (adriamycin) is the only therapeutic agent generally accepted to be of some use in its treatment (Olweny et al., 1980; Chlebowski et al., 1984) . Unfortunately, in the only prospective randomised trial of doxorubicin versus no antitumour therapy in HCC, it was shown that though doxorubicin prolonged the median survival of 3 weeks, it was associated with fatal toxicity in 25% of patients (Lai et al., 1988) . In that study, we also pointed out that decreasing the dose of adriamycin would only decrease the chance of tumour shrinkage in any potential responders. Although adriamycin was not an ideal drug for the treatment of HCC, so far no good alternative agent has been described.
Human lymphoblastoid interferon (IFN) was reported to inhibit the 3H-thymidine uptake by PLC/PRF/5 cell line in a dose-dependent manner (Dunk et al., 1986) . This study also showed slowing in tumour growth in athymic mice treated with IFN. For human HCC, two studies had been published using M2 IFN, one with five patients (four Asians) (Nair et al., 1985) and one with 16 South Africans (Sachs et al., 1985) . No regression was reported. The number of patients in both studies was small. There were also no comparison groups.
The aim of the present study is to compare the effect of IFN and doxorubicin in the survival, tumour regression and drug toxicity in 75 Chinese HCC patients.
Materials and methods

Patient selection
Seventy-five consecutive Chinese subjects with histologically proven HCC who fulfilled the following criteria were included in the study. (a) Their age were under 75 years old.
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(b) Their tumours were inoperable as assessed by ultrasonography, CT scan and/or hepatic arteriography (HAG) . (c) They had received no previous surgical resection or antitumour therapy of any kind. (d) Their Karnovsky scale was over 70%, i.e. the patient had to be ambulant and able to take care of most of his own daily needs. (e) Their bilirubin levels should not be over 50 gLmol 1' (normal< 30 gsmol I`). This criterion was chosen because a previous study of 211 Chinese HCC patients showed that a raised bilirubin was associated with rapid death (Lai et al., 1981) ; this was further confirmed by our study using doxorubicin (Lai et al., 1988 Criteria for tumour regression In patients surviving over 4 weeks, tumour regression was defined as at least 25% reduction in three of the following four criteria: (1) the product of the maximum diameter of the tumour and the diameter perpendicular to this in the sagittal plane; (2) the sum of the liver span as measured at the right (and the left if palpable) mid-clavicular line and at the xiphisternum; (3) serum AFP and/or ferritin levels; and (4) tumour size at diagnosis and at autopsy in the sagittal plane. There must also be no evidence of new or progressive metastases, especially on chest X-ray. Table I shows the demographic data of the 75 patients before the institution of treatment. There were no differences in any of the parameters in all three groups. Nineteen subjects presenting during the period of the study were excluded, 12 of these because of bilirubin levels of above 50 ,mol on presentation.
Statistical analyses were done using x2 test, Fisher's exact test, Student's t test, Mann-Whitney test and actuarial survival by SPSS (SPSS Inc., Chicago, IL, USA).
Results
The six patients with switching of drug therapy Three patients receiving doxorubicin had stable tumour until they received up to 495-505 mg m2 of doxorubicin. They were then switched over to r-IFN three times weekly. All three patients, aged 26, 28 and 56 years, died of intractable cardiac failure because of cardiomyopathy 1 week, 12 weeks and 8 months respectively after switching over to rIFN. The patients who survived for 12 weeks and 8 months had 25-50% and over 50% shrinkage of tumours respectively, both starting within 4 weeks of receiving rIFN.
Three patients receiving rIFN, one on the daily regime and two on the three times weekly regime, were switched over to doxorubicin at week 12 because of progressive disease. All continued to have progressive disease while on doxorubicin. Two died of progressive tumours at weeks 4 and 12 after switching over to doxorubicin. One patient, aged 37 years died of cardiomyopathy 29 weeks after switching over and receiving 505 mg m-2 of doxorubicin.
The 69 patients on single drug therapy The two groups receiving rIFN will be grouped together from this point onwards (except when specifically mentioned), as there were no significant differences in patient survival, tumour shrinkage or side-effects between the two regimes of rIFN.
Survival
The actuarial survival of the 22 patients receiving doxorubicin alone and of the 47 receiving rIFN alone is shown in Figure 1 Causes of death The causes of death are tabulated in Table III . There was a higher incidence of rupture of tumour in the rIFN group (17%) than in the doxorubicin group (0%). All eight patients with tumour rupture had autopsies. There was no evidence of tumour lysis, with six patients showing progressive tumours. The incidence of tumour rupture in rIFN-treated patients was not different from those receiving no treatment in a previous study (Lai et al., 1981) . The three patients on doxorubicin dying of septicaemia will be discussed below.
Side-effects andfatal complications of drug therapy A total of 28 patients were put on doxorubicin and 53 patients on rIFN. Their side-effects are listed in Table IV The two patients on doxorubicin who developed renal failure did so during the terminal stage of liver failure. The one patient on rIFN who developed renal failure was aged 64 years and had hyperuricaemia and a slightly raised serum creatinine of 0.15 jLmol 1' before treatment. After two doses of rIFN, he developed hyperkalaemia of 6.9 mmol 1-'. There was no evidence of tumour lysis. The rIFN was stopped. His renal function deteriorated in spite of lowering of the serum potassium. He died 2.5 weeks after initiation of rIFN.
The patient on rIFN who had dementia was the 67-yearold man who had rIFN for 110 weeks and over 75% tumour regression. He developed increasing irritability and later urinary incontinence at week 95. CT scan of the brain showed mild cerebral atrophy. rIFN was stopped at week 105. He died at the age of 69, his tumour remaining at 3 cm at death (Figure 3) . He was negative for antibodies against the human immunodeficiency virus (HIV). Table V shows the fatal complication associated with doxorubicin and rIFN. The causal relationship between the deaths due to renal failure and dementia with rIFN are not certain (see Discussion).
Discussion
The present trial was designed to study the effect of rIFN, in HCC. rIFN is reported to be of use in vitro (Dunk et al., 1986) , but was of no use in two uncontrolled trials in human HCC (Nair et al., 1985; Sach et al., 1985) . It is therefore essential to compare its effect with a standard agent for the treatment of HCC. Doxorubicin was chosen as it was the only agent generally accepted to be of some use. However, with the re-confirmation of the fatal side-effects of doxorubicin in this present study to be identical to our previous trial (Lai et al., 1988) , it would be preferable to compare rIFN treated patients with patients on no treatment.
Patient survival
There was no statistical difference in the survival curves of patients on doxorubicin and on rIFN (Figure 1 ). For those on rIFN, there was an improvement in the median survival rate from 4.8 to 8.3 weeks as well as a slight increase in the proportion surviving over 12 weeks. The poor median survival for both groups of patients, even after exclusion of patients with raised bilirubin levels from this trial, reconfirmed that our HCC patients presented late (Lai et al., 1981 (Lai et al., , 1988 . In the former study (Lai et al., 1981) , the median survival of 104 unselected patients with HCC was 3.5 weeks. However, patients with tumour regression (on rIFN) did show a tendency for longer survival. Unfortunately, there were no criteria by which to predict which patient would respond, and which would die early and therefore not benefit from treatment of any kind, even given the fairly stringent criteria by which we included patients for the trial. There are three different approaches to this difficult dilemma of treating HCC patients more profitably with less patient discomfort and longer survival. Firstly, since all 11 of our responders to rIFN showed tumour shrinkage within the first 4 weeks of treatment, it may be advisable to give all eligible patients a 4-8 week trial period in any future trials with rIFN. Those showing no response within 4-8 weeks may then be withdrawn from rIFN for the benefit of the patients. Since the two regimes of rIFN gave similar results, the three times weekly regime is to be recommended for patient convenience. Secondly, it is possible that the dose of rIFN can be reduced to decrease uncomfortable side-effects, mainly fatigue. The large doses of rIFN chosen in both regimes in this trial were justified by the in vitro finding that decrease in 3H-thymidine uptake by PLC/PRF/5 cells was dose-dependent (Dunk et al., 1986) . This is further confirmed by the ineffectiveness of the two previous trials in human HCC using lower dosages of IFN (Nair et al., 1985; Sacs et al., 1985) . Determination of the optimal dosage of rIFN for inducing tumour regression in human HCC will require a study on a much larger scale than the present trial.
A third, completely different, approach to improving patient survival is to detect subclinical HCC (SCHCC) by routine AFP and ultrasound screening of high risk subjects, specifically hepatitis B carriers. However, the local experience with AFP screening was disappointing (Lok & Lai, 1989) . Very few SCHCC were detected. They were often multicentric and/or in surgically inaccessible site, superimposed on grossly cirrhotic livers. In Shanghai, although the routine survey of AFP increased the number of SCHCC among HCC patients from 0% in 1961 -1970 to 17.7% in 1970 -1982 (Tang, 1985 , it must be stressed that even in the later period, the actual number of clinical HCC versus SCHCC patients was 466 to 100. The overall resectability rate of 30.9% in the 566 patients was therefore only slightly better than the 24.7% in those with clinical HCC (y2 = 4.622, P<0.05).
Thus, inoperable HCC presenting late will probably remain a major cancer problem in spite of vigorous application of early detection methods. Until the possible decrease in incidence of HCC with the widespread vaccination of infants with the hepatitis B vaccine (Lai, 1985) , rIFN is a superior agent to doxorubicin for HCC (see below), even if its prolongation of patient survival is limited.
Tumour regression Compared with doxorubicin, there was significantly more tumour regression and less tumour progression in the rIFN groups in this trial. rIFN induced tumour regression in 22% of our patients, with 10% having over 50% regression as required by the WHO standard. (If we include the three patients switched over from doxorubicin to rIFN, then 24.5% of patients had tumour regression, with 11.3% having over 50% regression.) The lack of regression in the two studies published using IFN in HCC may be due to the smaller size of patient samples and/or the lower dosages used in both studies (Nair et al., 1985; Sachs et al., 1985) .
The complete lack of tumour regression in all 28 patients receiving doxorubicin in this study may be due to the comparatively small sample of patients. However, even in a previous study of doxorubicin with 60 patients, only 8.3% had tumour regression with 3.3% having over 50% regression (Lai et al., 1988) . These figures are still much lower than those for rIFN in this study.
Side-effects andfatal complications of doxorubicin and rIFN The high fatal complication rate of 25% of patients treated with doxorubicin in this trial is identical to that in a previous study (Lai et al., 1988) . In both trials, the causes of death were neutropenia and cardiotoxicity. The degree of neutropenia was unpredictable from the previous courses of doxorubicin and therefore unpreventable. This also applied for the cardiotoxicity. Because of the 'escape' route of switching of drug therapy in this trial, none of the four patients dying of cardiotoxicity received more than the usually accepted 'non-cardiotoxic' dose of 500 mg m2. In spite of this, all eventually died of cardiomyopathy. Even for the 56-year-old patient who died of cardiac failure due to cardiomyopathy 8 months after switching over to rIFN, doxorubicin was still the most likely causal agent because (a) the patient's 2D echocardiogram showed the typical ventricular hypocontractility of doxorubicin-induced cardiomyopathy, (b) his ECG revealed no evidence of myocardial ischaemia and (c) it is well documented that doxorubicin-induced cardiomyopathy may occur as long as 12 months after cessation of therapy (Henderson & Frei, 1980) . This high fatality rate due to cardiotoxicity (4%) in spite of a 'non-cardiotoxic' dose is not observed in the Caucasian population. This may be due to the high dosages of doxorubicin that were used in our study, even though the dosages were the standard dosages recommended for HCC and even though we have tailored the dosages for patients with bilirubin levels above normal (see 'Protocol' above). A possible alternative explanation is the differences in racial susceptibility to doxorubicin. We would like to emphasise that doxorubicin should be used with extreme caution, especially in the presence of impaired hepatic functions.
In the rIFN group, the tolerance of the drug was good in most cases. This differs from the finding of Sachs et al. (1985) where seven out of 16 patients tolerated the drug badly. In our study, one patient had a wheezing attack and one had mental confusion with the first dose only. The degree of marrow suppression was less severe (P = 0.01217) and more transient than doxorubicin, most likely because rIFN is cytostatic whereas doxorubicin is cytocidal. Seven patients (13.2%) on rIFN had significant fatigue, with two requiring permanent reduction of dosage. This compares favourably with the 39.3% of the doxorubicin group who also had significant fatigue lasting 2-7 days after each injection. Mental confusion and fatigue are well documented neuropsychiatric complications with rIFN treatment (Adams et al., 1984; McDonald et al., 1987) . However, no organic changes or damages had been reported to date. In the present trial, one patient died at age 69 years of dementia, with CT scan showing mild cerebral atrophy. It is uncertain whether rIFN had any causal relationship with his dementia. His age and the demonstrable cortical atrophy as well as the absence of antibody against HIV are against rIFN as a causal factor. On the other hand, he had received a daily dose of 18 x 106 IU m 2 of rIFN for 105 weeks. The absolute possibility of organic cerebral damage with such a prolonged large dose of rIFN could not be ruled out. The casual relationship of rIFN with the other death due to renal failure following hyperkalaemia is also uncertain. rIFN can cause transient reversible renal failure. Our patient had hyperuricaemia and a mildly elevated serum creatinine before initiation of rIFN. The episode of hyperkalaemia following two doses of rIFN could not be due to tumour lysis as there was no evidence of tumour regression. It was this episode of hyperkalaemia that triggered off the fatal renal failure even though rIFN was stopped promptly. Thus, the relationship between the rIFN treatment and both deaths in this group remains uncertain. But even assuming that there was a direct causal relationship, rIFN caused death in only 3.8% of patients, much lower than the unacceptable 25% associated with doxorubicin therapy (P = 0.01383).
In conclusion, in the treatment of inoperable HCC in patients with relatively good Karnovsky scale and hepatic function, rIFN when compared with doxorubicin gave rise to slightly but not significantly better patient survival. It was associated with a significantly lower proportion of progressive tumour and a higher proportion of regressing tumour (12% between and 25-50% regression, and 10% over 50% regression). It was also a much safer drug. Most of its side-effects either showed tachyphylaxis or were mild and transient. It was associated with a much lower fatal complication rate than the 25% due to doxorubicin. Further trials of rIFN in inoperable HCC should be carried out to substantiate our findings as well as to determine the optimal dose. We are conducting a second trial comparing rIFN with no treatment in HCC patients.
